Novartis AG (NVS) Financials
Key financial figures for Novartis AG (Q3 2026).
Novartis grew Q3 net sales 4% to USD 14.5 billion with core operating income up 11% to USD 6.0 billion, and raised full-year core operating income guidance to in line to low single-digit growth (from a low single-digit decline). Net sales were USD 14,522m (+4% USD, +4% cc) versus USD 13,909m a year earlier; volume added 14 points, generic competition cost 9 points and pricing 1 point. Core operating income was USD 6,036m (+11% USD, +10% cc) at a 41.6% core margin versus 39.3% a year ago; core EPS was USD 2.46 versus USD 2.25 (+9% USD, +8% cc). IFRS operating income fell to USD 1,843m from USD 4,501m (-59%) and net income to USD 1,196m from USD 3,930m (-70%), mainly on a USD 1.9 billion partial impairment of the del-desiran IPR&D asset after the Phase III HARBOR study in DM1 missed its primary endpoint. On the outlook: Full-year 2026 (growth versus prior year in constant currencies, barring unforeseen events): net sales expected to grow low single-digit (unchanged); core operating income expected to be in line to grow low single-digit, raised from a decline of low single-digit. If late-October exchange rates prevail, the foreign exchange impact is expected to be positive 1 percentage point on net sales and positive 1 percentage point on core operating income. Figures are for Q3 2026, as Novartis AG reported them.
- Revenue
- $15.0B
- Net Income
- $1.2B
- EPS
- $0.63
- Total Assets
- $117.1B
- Operating Cash Flow
- $5.5B
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $15.0B | $1.2B | $0.63 | 12.26% | $4.8B |
| Q2 FY2026 | $14.4B | $3.3B | $1.71 | 32.84% | $5.6B |
| Q1 FY2026 | $13.5B | $3.2B | $1.65 | 31.31% | $2.9B |
| Q4 FY2025 | $13.3B | $2.4B | $1.25 | 26.4% | $1.6B |
| Q3 FY2025 | $14.4B | $3.9B | $2.02 | 31.35% | $5.7B |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $54.8B | $14.1B | $7.19 | 31.15% | $17.7B |
| FY2024 | $51.7B | $11.9B | $5.87 | 28.12% | $13.8B |
| FY2023 | $46.7B | $14.8B | $7.10 | 20.94% | $11.7B |
Frequently asked questions
What was Novartis AG's revenue last quarter?
Novartis AG reported revenue of $15.03 billion for Q3 FY2026, up 4.7% from the same period a year earlier.
Is Novartis AG profitable?
Yes. Novartis AG reported net income of $1.20 billion for Q3 FY2026, a net margin of 8% on revenue.
How has Novartis AG's margin trended?
Operating margin was 12.26% in Q3 FY2026, compared with 31.35% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Novartis AG generate?
Novartis AG generated free cash flow of $4.76 billion in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Novartis AG on SentiSense, with up to forty quarters and twenty fiscal years of history.